Getting Started: What You Need to Know About MAT
Medication-assisted treatment (MAT) is the standard of care for incarcerated individuals with opioid use disorder. To reduce legal liability, provide quality care, and prevent overdoses, administrative and health staff may begin exploring, starting, or expanding an MAT program. New regulations expanding the ability to prescribe buprenorphine are making MAT programs more of an expectation from the public and judiciary and more convenient than ever before.
This expert panel will provide an essential introduction to the provision of FDA-approved buprenorphine, methadone, and naltrexone in correctional environments, including a background on the use of each medication for MAT, evidence of effectiveness in correctional environments, varying regulatory restrictions, and the importance of continuity of care upon release.
• Review the opioid epidemic in the United States
• Summarize the three medications used for MAT, including regulatory restrictions
• Explore the effectiveness of MAT in corrections
Claire Wolfe, MA, MPH, CCHP, Program Manager, NCCHC Resources
Richard Forbus, CCHP, Vice President of Program Development, National Commission on Correctional Health Care
Robert Simon MEd, NCC, CCHP, Opioid Treatment Program Manager, National Commission on Correctional Health Care
$65 ($55 for CCHPs), includes access to the power point presentation, the webinar recording and CE credit – 1.00 hours for ACCME, ANCC, APA, and CCHP.